# China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering

- Link: https://www.thailand-business-news.com/pr-news/china-sxt-pharmaceuticals-inc-announces-12-million-registered-direct-offering
- Published: 2026-10-08T20:22:00+07:00
- Author: PR Newswire

TAIZHOU, China, Oct. 8, 2026 /PRNewswire/ — China SXT Pharmaceuticals Inc. (NASDAQ:
SXTC) (the "Company"), today announced that it has entered into a definitive agreement
with certain institutional investors for the purchase and sale of an aggregate of
8,000,000 Class A ordinary shares of the company, no par value per share (the "Shares")(
or pre-funded warrants in lieu thereof), at a purchase price of $1.50 per share 
in a registered direct offering.

The Company also agreed to issue to the same investors 8,000,000 warrants (the "
Warrants") with an exercise price of $1.50 per share. The Warrants will be immediately
exercisable upon issuance and have a 1-year term from the date of issuance. Each
warrant has a zero cash exercise option permitting the holder to acquire up to 9
Class A shares.

The aggregate gross proceeds to the Company of this offering are expected to be 
approximately $12 million, before deducting placement agent fees and other offering
expenses payable by the Company. Investors will have an additional purchase right
to acquire up to $12 million of securities on the same terms and conditions during
the 30-day period after closing. The offering is expected to close on or about October
9, 2026, subject to the satisfaction of customary closing conditions.

Univest Securities, LLC is acting as the sole placement agent.

The registered direct offering is being made pursuant to a shelf registration statement
on Form F-3 (File No. 333-291428) previously filed by the Company with the U.S. 
Securities and Exchange Commission ("SEC") and became effective on December 1, 2025.
A final prospectus supplement and accompanying prospectus describing the terms of
the proposed offering will be filed with the SEC and will be available on the SEC’s
website located at [http://www.sec.gov](http://www.sec.gov/). Electronic copies 
of the final prospectus supplement and the accompanying prospectus may be obtained,
when available, by contacting Univest Securities, LLC at [info@univest.us](https://www.thailand-business-news.com/pr-news/info@univest.us),
or by calling +1 (212) 343-8888.

This press release does not constitute an offer to sell or the solicitation of an
offer to buy, nor will there be any sales of such securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of such jurisdiction. Copies of the prospectus
supplement relating to the registered direct offering, together with the accompanying
base prospectus will be filed by the Company and, upon filing, can be obtained at
the SEC’s website at [www.sec.gov](http://www.sec.gov/).

**About China SXT Pharmaceuticals Inc.**

Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China
SXT Pharmaceuticals Inc. is an innovative pharmaceutical company focusing on the
research, development, manufacture, marketing and sales of traditional Chinese medicine
pieces, which is a type of Traditional Chinese Medicine that has been processed 
to be ready for use. For more information, please visit [www.sxtchina.com](https://www.sxtchina.com/).

**Forward-Looking Statements**

Certain statements in this announcement are forward-looking statements. These forward-
looking statements involve known and unknown risks and uncertainties and are based
on current expectations and projections about future events and financial trends
that the Company believes may affect its financial condition, results of operations,
business strategy and financial needs. Investors can identify these forward-looking
statements by words or phrases such as "may," "will," "expect," "anticipate," "aim,""
estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely 
to" or other similar expressions. The Company undertakes no obligation to update
forward-looking statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law. Although the Company
believes that the expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn out to be correct,
and the Company cautions investors that actual results may differ materially from
the anticipated results and encourages investors to review other factors that may
affect its future results in the Company’s registration statement and in its other
filings with the U.S. Securities and Exchange Commission.

**China SXT Pharmaceuticals Inc.Feng Zhou, Chief Executive Officer
Email: [fzhou@sxtchina.com](https://www.thailand-business-news.com/pr-news/fzhou@sxtchina.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering ](http://www.prnasia.com/story/archive/5066770_CN66770_0?rand=184833)